Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

Background: Heterologous prime-boost SARS-CoV-2 vaccination is a widely accepted strategy during the COVID-19 pandemic, which generated a superior immune response than homologous vaccination strategy. Objective: To describe immunogenicity of heterologous prime-boost vaccination with inactivated vacc...

Full description

Bibliographic Details
Main Authors:	Thanyawee Puthanakit, Rapisa Nantanee, Peera Jaru-Ampornpan, Napaporn Chantasrisawad, Jiratchaya Sophonphan, Thutsanun Meepuksom, Thidarat Jupimai, Pimpayao Sodsai, Suvaporn Anugulruengkitt, Nattiya Hirankarn
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Vaccine: X
Subjects:	SARS-CoV-2 vaccine Adolescent Neutralizing antibody titer Anti-SARS-CoV-2 IgG CoronaVac vaccine BNT162b2 vaccine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590136222000717

Similar Items

Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
by: Rapisa Nantanee, et al.
Published: (2023-12-01)

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
by: Thanyawee Puthanakit, et al.
Published: (2022-09-01)

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
by: Rapisa Nantanee, et al.
Published: (2022-06-01)

Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster
by: Napaporn Chantasrisawad, et al.
Published: (2022-12-01)

Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants
by: Chomchanat Tubjaroen, et al.
Published: (2022-11-01)

The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
by: Napaporn Chantasrisawad, et al.
Published: (2023-05-01)

Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents
by: Pavinee Assavavongwaikit, et al.
Published: (2022-07-01)

Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers
by: Watsamon Jantarabenjakul, et al.
Published: (2022-04-01)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
by: Napaporn Chantasrisawad, et al.
Published: (2022-05-01)

SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study
by: Ireri Thirión-Romero, et al.
Published: (2023-11-01)

Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency
by: Pierpaolo Di Micco, et al.
Published: (2021-09-01)

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients
by: Anussara Prayongrat, et al.
Published: (2023-06-01)

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
by: Huang Liang, et al.
Published: (2022-12-01)

Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model
by: Devanshi R. Patel, et al.
Published: (2024-03-01)

Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2
by: Nura A. Mohamed, et al.
Published: (2022-07-01)

Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPS<sup>TM</sup>) SARS-CoV-2 Vaccine
by: Brian Cieslewicz, et al.
Published: (2022-07-01)

Self-Reported SARS-CoV-2 Vaccination Is Consistent with Electronic Health Record Data among the COVID-19 Community Research Partnership
by: Ashley H. Tjaden, et al.
Published: (2022-06-01)

Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern
by: Abdul Aziz Al-Fattah Yahaya, et al.
Published: (2023-02-01)

Is SARS-CoV-2 Vaccination of Subjects with a Prior History of Allergies Dangerous? Experiences in the Veneto Region of Italy
by: Silvia Cocchio, et al.
Published: (2023-03-01)

Myositis after SARS-CoV-2 vaccination occurs more frequently than assumed and is probably causally related
by: J. Finsterer, et al.
Published: (2023-09-01)

Neuroretinitis after the second injection of a SARS-CoV-2-vaccine: A case report
by: Chaeyeon Lee, et al.
Published: (2022-09-01)

RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System
by: Harsha Raheja, et al.
Published: (2022-08-01)

Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
by: Hazel M. Dockrell, et al.
Published: (2022-05-01)

Social Response to the Vaccine against COVID-19: The Underrated Power of Influence
by: Dimitra S. Mouliou, et al.
Published: (2021-12-01)

Coronavirus vaccine development: from SARS and MERS to COVID-19
by: Yen-Der Li, et al.
Published: (2020-12-01)

No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study)
by: Kendall D. Kling, et al.
Published: (2023-01-01)

Association between virus variants, vaccination, previous infections, and post-COVID-19 risk
by: Sophie Diexer, et al.
Published: (2023-11-01)

Potential Immunogenic Activity of Computationally Designed mRNA- and Peptide-Based Prophylactic Vaccines against MERS, SARS-CoV, and SARS-CoV-2: A Reverse Vaccinology Approach
by: Taimoor Khan, et al.
Published: (2022-04-01)

Human Coronavirus Spike Protein Based Multi-Epitope Vaccine against COVID-19 and Potential Future Zoonotic Coronaviruses by Using Immunoinformatic Approaches
by: Zulqarnain Baloch, et al.
Published: (2022-07-01)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01)

Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight
by: Chunting He, et al.
Published: (2020-07-01)

Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study
by: Erika Molteni, et al.
Published: (2022-08-01)

Effect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review
by: Andreas G. Tofarides, et al.
Published: (2022-12-01)

The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia’s Vaccine Rollout Slower than That of Other Nations?
by: Elza Mikule, et al.
Published: (2021-08-01)

Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2
by: Theocharis G. Konstantinidis, et al.
Published: (2021-06-01)

Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval
by: Ebenezer Tumban
Published: (2020-12-01)

COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran
by: Atefeh Vaezi, et al.
Published: (2021-12-01)

Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study
by: Giovanni Corrao, et al.
Published: (2022-02-01)

COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type
by: Areg A. Totolian, et al.
Published: (2023-10-01)

Vaccination Confidence among Healthcare Workers: Results from Two Anamnestic Questionnaires Adopted in the COVID-19 and Influenza Campaign
by: Ihab Mansour, et al.
Published: (2022-10-01)